Skip to content
DataLookout
Menu

NCT07370155

Study Evaluating Safety & Tolerability of Migaldendranib in Healthy Volunteers

StatusCompleted
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 28 words Show 4 more changesShow less
    • Trial completed
    • Final enrollment: 6 participants (planned 36)
    • Study completion date changed from estimate of Oct 10, 2026 to Oct 27, 2026
    • Secondary endpoints: details revised at 1 of 5 entries
  2. Minor Enrollment closed, study ongoing
    • Primary completion moved earlier from Aug 13, 2026 to Mar 5, 2026
    • Site details revised
    v4
  3. Notable Recruitment opened
    • Primary completion pushed from May 13, 2026 to Aug 13, 2026
    • Study completion pushed from Jun 10, 2026 to Oct 10, 2026
    • Study sites: 0 to 1
    v3
  4. Notable Primary endpoint revisedv2 Show 5 more changesShow less
    • Interventions: MGB 200 mg (Drug), MGB 200 mg + ALT-B4 (Drug), MGB 400 mg (Drug), MGB 400 mg + ALT-B4 (Drug), MGB 600 mg (Drug), MGB 600 mg + ALT-B4 (Drug) to MGB 200 mg (Drug), MGB 400 mg (Drug), MGB 600 mg (Drug)
    • Secondary endpoints revised (5)
    • Study description shortened, about 15 words
    • Study arms: 6 to 3
    • Study title shortened, about 3 words
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Safety and Tolerability of MGB
Timeframe: Varying timepoints through end of treatment, up to approximately 22 days.

Secondary (5)

Pharmacokinetic Parameter Area Under the Curve (AUC) for MGB
Pharmacokinetic Parameter Maximum Concentration (Cmax) for MGB
Pharmacokinetic Parameter Time to Maximum Concentration (Tmax) for MGB
Pharmacokinetic Parameter Total Clearance (CL) for MGB
Pharmacokinetic Parameter Apparent Terminal Half-life (t1/2) for MGB

Arms and interventions

MGB 200 mgExperimental

Participants receive MGB 200 mg administered subcutaneously once weekly on Days 1, 8, and 15 to evaluate safety, tolerability, and pharmacokinetics.

MGB 400 mgExperimental

Participants receive MGB 400 mg administered subcutaneously once weekly on Days 1, 8, and 15 following Safety Review Committee approval.

MGB 600 mgExperimental

Participants receive MGB 600 mg administered subcutaneously once weekly on Days 1, 8, and 15, contingent upon acceptable safety and tolerability in prior cohorts.

Drugs: MGB 200 mg, MGB 400 mg, MGB 600 mg

Sites

1 site in 1 country

  • Nucleus Network (Brisbane)Brisbane, Queensland, Australia